Global Sexually Transmitted Disease Market- By Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus), By Location (Laboratory Testing and Point of Care Testing), By Devices (Laboratory Devices and Point of Care (POC) devices), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Sexually Transmitted Disease Market Size is expected to be worth around USD 171 Bn by 2032 from USD 95 Bn in 2022, growing at a CAGR of 6.17% during the forecast period from 2022 to 2032.

The occurrence of STDs has increased due to the rise in unprotected sex. It drives the growth of the global sexually transmitted disease testing market. For a person who does not have any symptoms but has unprotected intercourse, the doctor will typically recommend STD testing. Immunoassays, Viral load monitoring, genotyping, and molecular diagnostics are some of the STD diagnostics available in the market.

The need for sexually transmitted diseases (STDs) testing is also fueled by increased public awareness and their education. Additionally, the market expansion is expected to be driven by increased government initiatives, patient awareness through education campaigns, and increased STD prevalence worldwide. In the past ten years, the incidence and prevalence of sexually transmitted diseases have significantly increased. In response to the rising incidence of STDs, several countries are putting their efforts into establishing national screening programs to increase access to treatment. Additionally, STD services have benefited from favorable reimbursement policies. The global market for STD testing is expanding strongly due to these factors.

Key Takeaways

• Market Size and Growth: The global Sexually Transmitted Disease (STD) market is projected to grow significantly, with an expected worth of around USD 171 billion by 2032, compared to USD 95 billion in 2022, at a CAGR of 6.17% during the forecast period from 2022 to 2032.
• Drivers of Growth: The rise in unprotected sex and increased public awareness about STDs are driving the growth of the global STD testing market. Government initiatives, education campaigns, and rising STD prevalence are also contributing to market expansion.
• Type Analysis: Chlamydia is the dominant type of STD tested in 2022 due to a lack of barrier protection and public awareness. However, syphilis is projected to grow at a robust CAGR, accounting for over 20% of the market by 2022.
• Location of Testing: Laboratory testing is expected to hold the majority of the global STD testing market, as most diagnostic tests are conducted in laboratories.
• Market Segments: The key market segments include disease type (Chlamydia, Gonorrhea, Herpes Simplex Virus, etc.), location of testing (Laboratory Testing, Point of Care Testing), and devices (Laboratory Devices, Point of Care Devices).
• Prevalence: The prevalence of STDs is rapidly rising globally, primarily among young adults. More people are getting tested due to unprotected sex, a lack of awareness, and multiple partners, which is fueling market growth.
• Opportunities: Rising demand for STD diagnostics and increased awareness of the disease are creating opportunities for market growth, with advancements in diagnostic devices and treatment strategies playing a significant role.
• Trends: Key trends in the market include the increasing prevalence of STDs, greater awareness through education campaigns, and government initiatives. Advanced diagnostic tools and improved treatment strategies are also contributing to market growth.
• Technological Advancements: Nucleic acid amplification tests (NAATs) are being used for more sensitive and specific STD diagnostics. They are especially valuable for identifying infections like chlamydia and gonorrhea.
• Regional Analysis: North America, particularly the United States, dominates the global STD testing market, with North America holding 52.2% of revenue in the diagnostics market. China is expected to lead the market in the Asia-Pacific region with a CAGR of 7.2% between 2022 and 2032.

Type Analysis

Chlamydia, herpes simplex virus, gonorrhea, human papillomavirus (HPV), syphilis, and other diseases (human immunodeficiency virus, chancroid, hepatitis B, and trichomoniasis) are the several types of STDs that can be tested. However, due to a lack of barrier protection and public knowledge of STDs, the chlamydia sector accounts for most of the STDs testing market share in 2022.

The STDs testing market is predicted to expand primarily due to the increased incidence of numerous illnesses, including trichomonas vaginitis, gonorrhea, vaginitis, syphilis, chlamydia, herpes simplex virus, chancroid, and human papillomavirus. Gonorrhoea, syphilis, and chlamydia are bacterial STIs, whereas genital herpes, genital warts (HPV), HIV, and hepatitis are viral STIs. This is because the blood, semen, and vaginal fluid all contain the bacteria that cause STIs.

Chlamydia-related STDs accounted for most of the market’s revenue in 2014, estimated to be over US$ 6 billion. However, due to the rising frequency of syphilis infections worldwide, the diagnosis of sexually transmitted illnesses brought on by syphilis is on the rise. As a result, it is projected to account for over 20% of the market by 2022, growing at a robust CAGR.

Location of Testing

According to the testing location, the market is divided into point of care (POC) testing and laboratory testing. The laboratory testing segment is anticipated to hold most of the global STD testing market throughout the forecast period. Additionally, it is expected that the STD testing demand will rise because the majority of diagnostic tests are carried out in laboratories.

Key Market Segments

Based on Disease Type

• Chlamydia
• Gonorrhea
• Herpes Simplex Virus
• Syphilis
• Human Papillomavirus
• Cancroid
• Other Diseases

Based on Location

• Laboratory Testing
• Point of Care (POC) Testing

Based on Devices

• Laboratory Devices
• Point of Care (POC) Devices

Drivers

The prevalence of sexually transmitted infections is rapidly rising among people

Worldwide, sexual and reproductive health is significantly impacted by sexually transmitted infections. More than 55% of reported cases of sexually transmitted diseases were among young adults aged 15 to 24 in 2019. In 2020, more than 374 million cases of one of the four STIs were reported by the World Health Organization (WHO). Most patients were caused by chlamydia (129 million), followed by gonorrhea, trichomoniasis, and syphilis. In 2018, infections with the human papillomavirus (HPV) were linked to 570,000 cases of cervical cancer and more than 311,000 deaths from the disease. The Cleveland Clinic estimates that more than 20 million new STD infections occur each year. Hepatitis B was the cause of the deaths of 820,000 people in 2019, most of whom had cirrhosis and hepatocellular carcinoma. The prevalence of all these infections among people is rapidly rising due to unprotected sex, a lack of awareness, and the intimacy of multiple partners. As a result, more people are getting tested for STDs, which is helping the market grow.

Restraints

False results of STD testing

There is a possibility that tests will return false positive results, indicating the existence of an infection when there isn’t one. A false negative result, in which an infection is present but is not detected, is a more serious possibility. A false negative result indicates that the undiagnosed STD will probably not be treated.

Opportunity

Rising demand for STD diagnostics and increasing awareness of the disease

The Sexually Transmitted Diseases Diagnostics market share is expected to boost during the forecast period due to rising demand for STD diagnostics and increasing public awareness of the disease.

A significant increase in patient checkups, government initiatives, campaigns, and raising awareness of infection and other sexually transmitted diseases are driving the diagnostics market share.

Globally, the share of the diagnostics market for sexually transmitted diseases has increased over the past decade. However, the market outlook is being significantly altered by advancements in diagnostic devices for sexually transmitted infections.

Increasing public awareness and patient education are two additional significant factors driving the market for diagnostics for sexually transmitted diseases (STDs). Additionally, an increase in the global prevalence of sexually transmitted diseases (STDs), increased awareness of patients through education programs, and increased government initiatives are anticipated to increase the demand for diagnostics.

In the upcoming forecast period of 2022 to 2032, a significant increase in the share of the diagnostics market for sexually transmitted diseases is anticipated. It is expected that an increase in the demand for products that diagnose sexually transmitted infections will result from the development of more advanced diagnostic tools and improved treatment strategies.

Trends

Market trends involve different tests used to identify STDs with technological advancements.

Across the world, HIV remains a considerable public concern. According to WHO, most people who have aids are from low- and middle-income countries, while 66% were Sub-Saharan African residents in 2019. Every third of all new HIV infection is from South Africa. Due to the greater diagnostic rate, the number of patients was rising drastically. As per the reports of GHE Charity’s tbfacts.org website, 7.5 million individuals were projected to be living with AIDS in the year 2018. The anticipated growth of the STDs Testing Market and the increasing awareness about STD testing are key trends that are driven by the rising prevalence of STDs worldwide, an increase in patient awareness through education campaigns, and a surge in government initiatives.

The nucleic acid amplification test (NAAT) is a molecular diagnostic used to diagnose various STDs along with chlamydia. In addition, it is a molecular test used to identify the DNA of Chlamydia Trachomatis and its genetic information. The test process is typically more sensitive and specific than previous chlamydia tests. It is conducted on a vaginal swab extricated from women for the pelvic examination.

Direct DNA probes and molecular testing, or NAATs, are the most sensitive tests for T. vaginalis and are the most crucial factor in recognizing these infections. In addition, using different nucleic acid amplification techniques, samples taken for testing gonorrhea and chlamydial infections can also be used to screen for T. vaginalis. In women, NAATs may specifically utilize both vaginal samples and urine. However, it is unauthorized to use all the male samples, and only a few have been authorized for utilization.

Regional Analysis

North America is dominating the sexually transmitted disease testing market globally.

Growth of the market industry is estimated across the countries like North America, Asia Pacific, Europe, and the rest of the world. However, because of the rising demand for STD diagnostic tests, the American is anticipated to hold the majority of the market share, with 52.2 % revenue in the diagnostics market. In addition, the United States is anticipated to increase regional demand for diagnostics for STDs. As a result, in the Sexually Transmitted Diseases Diagnostics market, the United States holds a 7.7% CAGR share between 2022 and 2032 during the forecast period.

Since it is the most prevalent infection in the United States, chlamydia-type STD infections will likely rise. Therefore, the share of the STDs diagnostics market that will grow during the forecast period comes from girls between the ages of 15 and 25 who have been found to be infected with this disease.

Asia is anticipated to hold the second-largest share of the sexually transmitted diseases diagnostics market. During the forecast period, China’s extensive inventory of STD diagnostic tests is expected to increase demand of market in the region. As a result, the China market is likely to dominate the STD diagnostics market at a CAGR of 7.2% between 2022 and 2032.

Compared to North America and the US market, other regions, such as the UK, South Korea, and Japan, are anticipated to have a lower demand for STD diagnostics during the forecast period. The STD diagnostics market outlook in this region is primarily based on ignorance, and delays in testing and treatment are reducing the market share.

Key Regions

North America

• The US
• Canada

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Mexico
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

In the upcoming forecast period of 2022 to 2032, key market players are anticipated to increase the market share for diagnostics for sexually transmitted diseases.

To expand their share of the market for diagnostics for sexually transmitted diseases, these businesses are forming partnerships, joint ventures, and other kinds of partnerships. The CT/NG test for sexually transmitted diseases has been confirmed by the US FDA for use in detecting infection. Major Companies operating in the globally sexually transmitted disease diagnostics market which contribute to market growth include Qiagen NV, Bio-Rad Laboratories, Dickinson and Company, Hologic Inc., Diasorin S.P, F. Hoffmann La Roche Ltd., Merck And Co. Inc., Gilead Sciences Inc., Inovio Pharmaceuticals Inc., BIOGENIX Inc. Pvt., AbbVie Inc., BIOGENIx Inc. Pvt. Ltd., Biotech Co. Ltd., RayBiotech Life Inc., CTK Biotech Inc., Everlywell Inc., Thermo Fisher Scientific Inc., AccuBioTech Co. Ltd., Hangzhou Biotest Biotech Co. Ltd., Roche Holdings AG, AdvaCare Pharma, Inc. Siemens AG, Becton Dickinson, MedMira Inc., Biomérieux SA, Orasure technologies, inc., and others. Due to rising global demand, sales of diagnostic and testing products for sexually transmitted diseases will likely increase.

The following are some recent developments in the diagnostics market for sexually transmitted diseases:

In March 2021, “National Alliance of State and Territorial AIDS Directors” (NASTAD) and “Building Healthy Online Communities” launched TakeMeHome, a free home delivery program for HIV and STD test kits.

In September 2020, the sexual health company Ash introduced STI at-home testing kits. Before receiving individualized diagnostics, the respondent must complete an online questionnaire as part of the exam.

Key Industry Development

• In May 2022, Becton, Dickinson, and Company announced the US launch of the BD COR MX instrument. It is a fully automated and high-throughput infectious disease molecular diagnostics platform and a new analytic instrument option for the BD COR System. The test is a single test that detects the three most significant non-sexually transmitted infections (STIs), they are, Trichomonas vaginalis (TV), Neisseria gonorrhea (GC), and Chlamydia trachomatis (CT). These three STIs possess a range of adverse patient outcomes, from increased risk of HIV to pregnancy complications.

Listed below are some of the most prominent sexually transmitted disease testing industry players.

Market Key Players

• Bio-Rad Laboratories, Inc.
• Dickinson and Company
• Hologic Inc.
• Diasorin S.P
• F. Hoffmann La Roche AG.
• Merck And Co. Inc.
• Gilead Sciences Inc.
• Inovio Pharmaceuticals Inc.
• BIOGENIX Inc. Pvt.
• Other Key Players.

Report Scope